Emerald Bioscience to Present at the 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Forum
January 30, 2020 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...
Emerald Bioscience Provides Update on Recent Progress and Expected 2020 Milestones
January 13, 2020 08:30 ET
|
Emerald Bioscience, Inc.
Company prepares to enter the clinic in 2020 to test NB1111 (THCVHS) in glaucoma Preclinical formulation testing proprietary analog of CBD examining the utility of CBDVHS in the eye, brain, and...
Emerald Bioscience to Present at Biotech Showcase 2020
January 09, 2020 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...
Emerald Bioscience Announces Financing Update and Board Re-organization
December 23, 2019 08:30 ET
|
Emerald Bioscience, Inc.
Emerald Health Sciences To Exercise 40.8 Million Warrants, Reducing Outstanding Debt, As Company Changes Name to Embi Pharmaceuticals Punit Dhillon Assumes Board Chairmanship as Dr. Avtar Dhillon...
Emerald Bioscience Inc. Announces Cannabidiol-Valine-Hemisuccinate Possesses Enhanced Anti-Seizure Activity when Compared with Cannabidiol (CBD) in the StemoniX Human Neural Tissue Platform
December 10, 2019 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
Emerald Bioscience Reports its Proprietary Analog of Cannabidiol, Cannabidiol-Valine-Hemisuccinate (CBDVHS), Exhibits Greater Potency and Antifibrotic Activity than Cannabidiol (CBD) in Biomarker Studies in Human Ocular Donor Tissues
December 09, 2019 08:30 ET
|
Emerald Bioscience, Inc.
CBDVHS Also Displayed Superior Anti-Inflammatory Activity When Compared to CBD Indicating Potential Use in Diseases of the Retina Unlike CBD, CBDVHS was not Associated with Biomarkers Related to...
Emerald Bioscience Announces $2.0 Million Registered Direct Offering
November 21, 2019 09:12 ET
|
Emerald Bioscience, Inc.
Long Beach, CA, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based...
Emerald Bioscience to Present at Cowen 2nd Annual Boston Cannabis Conference
November 04, 2019 08:30 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications,...
Emerald Bioscience to Present Research Data Related to its Glaucoma Drug Candidate, NB1111, at 2019 American Association of Pharmaceutical Scientists
October 30, 2019 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...
Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model
October 15, 2019 08:35 ET
|
Emerald Bioscience, Inc.
LONG BEACH, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...